Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenuePayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Drugs Made In America Acquisition (DMAA) Current Assets (2024 - 2025)

Drugs Made In America Acquisition filings provide 2 years of Current Assets readings, the most recent being $12191.0 for Q4 2025.

  • Quarterly Current Assets rose 144.26% to $12191.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12191.0 through Dec 2025, up 144.26% year-over-year, with the annual reading at $12191.0 for FY2025, 144.26% up from the prior year.
  • Current Assets hit $12191.0 in Q4 2025 for Drugs Made In America Acquisition, down from $28196.0 in the prior quarter.
  • Across five years, Current Assets topped out at $71019.0 in Q1 2025 and bottomed at $4991.0 in Q4 2024.